Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year Low – Should You Sell?

Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s stock price hit a new 52-week low on Tuesday . The company traded as low as $20.25 and last traded at $20.09, with a volume of 133465 shares traded. The stock had previously closed at $21.26.

Wall Street Analyst Weigh In

A number of analysts recently commented on SYRE shares. Robert W. Baird lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Wedbush restated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Spyre Therapeutics presently has a consensus rating of “Buy” and an average target price of $54.83.

Spyre Therapeutics Trading Down 4.2 %

The company has a 50-day moving average of $22.72 and a 200-day moving average of $26.97. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -2.72 and a beta of 2.85.

Institutional Investors Weigh In On Spyre Therapeutics

A number of hedge funds have recently bought and sold shares of SYRE. Driehaus Capital Management LLC increased its stake in shares of Spyre Therapeutics by 308.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,803,655 shares of the company’s stock valued at $65,269,000 after acquiring an additional 2,116,575 shares during the last quarter. FMR LLC lifted its position in shares of Spyre Therapeutics by 15.4% during the 4th quarter. FMR LLC now owns 8,801,266 shares of the company’s stock worth $204,893,000 after buying an additional 1,177,385 shares during the last quarter. Jefferies Financial Group Inc. increased its holdings in Spyre Therapeutics by 167.6% in the 4th quarter. Jefferies Financial Group Inc. now owns 1,216,954 shares of the company’s stock worth $28,331,000 after purchasing an additional 762,147 shares in the last quarter. Wellington Management Group LLP raised its holdings in Spyre Therapeutics by 89.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,507,200 shares of the company’s stock worth $44,327,000 after purchasing an additional 711,254 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new position in Spyre Therapeutics during the fourth quarter worth $10,864,000. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).